
CITATION REPORT List of articles citing



DOI: 10.1016/j.jhep.2019.02.014 Journal of Hepatology, 2019, 70, 1222-1261.

Source: https://exaly.com/paper-pdf/73464921/citation-report.pdf

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper IF	Citations
468	Drug-Drug Combinations can Enhance Toxicity as shown by Monocyte-Derived Hepatocyte-like Cells from Patients with Idiosyncratic Drug-Induced Liver Injury. 2019 ,	7
467	Roussel Uclaf Causality Assessment Method for Drug-Induced Liver Injury: Present and Future. 2019 , 10, 853	41
466	Hepatotoxicity of immune check point inhibitors: Approach and management. 2019 , 51, 1074-1078	19
465	Menotrophin Induced Autoimmune Hepatitis. 2019 , 2019, 7343805	1
464	The Management of Glucocorticoid Therapy in Liver Failure. 2019 , 10, 2490	6
463	Drug Induced Liver Injury Attributed to a Curcumin Supplement. 2019 , 2019, 6029403	7
462	Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 Inhibitors. 2019 , 10, 1235	16
461	Drug-induced liver injury. 2019 , 47, 734-739	2
460	Drug-induced liver injury. 2019 , 5, 58	148
459	Abklbung erhbter Leberwerte Lipdate 2019. 2019 , 17, 43-50	
458	Perioperative management and anaesthetic considerations for adult patients with Gilbert syndrome and oral cancer: review and case report. 2019 , 33, 1182-1186	2
457	Reply. 2019 , 157, 1439-1440	1
456	EASL Clinical Practice Guideline: Occupational liver diseases. <i>Journal of Hepatology</i> , 2019 , 71, 1022-1037 _{13.2}	ļ 11
455	Drug-Induced Liver Injury: Biomarkers, Requirements, Candidates, and Validation. 2019, 10, 1482	31
454	An electronic medical records-based approach to identify idiosyncratic drug-induced liver injury in children. 2019 , 9, 18090	2
453	[Gastrointestinal complications of the new immune checkpoint inhibitor therapies]. 2019, 144, 1731-1736	1
452	Prolonged interval of total bilirubin decline is an early independent predictive factor of chronic persistent drug-induced liver injury. 2020 , 50, 224-232	3

(2020-2020)

451	Diagnostic and prognostic assessment of suspected drug-induced liver injury in clinical practice. 2020 , 40, 6-17	16
450	Biologic and Checkpoint Inhibitor-Induced Liver Injury: A Systematic Literature Review. 2020 , 4, 172-184	19
449	Characterization of auto-immune hepatitis associated with the use of anti-TNF⊞ agents: An analysis of 389 cases in VigiBase. 2020 , 19, 102460	9
448	Liver Histology: Diagnostic and Prognostic Features. 2020 , 24, 61-74	8
447	Research advances in the association of drug-induced liver injury with polymorphisms in human leukocyte antigen. 2020 , 81, 106037	1
446	Higher seroprevalence of hepatitis E virus in autoimmune hepatitis: Role of false-positive antibodies. 2020 , 40, 558-564	8
445	Atorvastatin associated with gamma glutamyl transpeptidase elevation in a hyperlipidemia patient: A case report and literature review. 2020 , 99, e22572	3
444	Hepatic adverse drug reactions in Malaysia: An 18-year review of the national centralized reporting system. 2020 , 29, 1669-1679	3
443	[Management of immune checkpoint inhibitors-induced liver toxicity in cancer]. 2020, 107, 1056-1068	
442	Rechallenge of voriconazole successfully tolerated after hepatic toxicity. 2020 , 31, 101191	O
441	Appropriate chemopreventive strategy for anti-tubercular therapy related liver injury is unsettled: Results from a systematic review and network meta-analysis. 2020 , 13, 1253-1262	2
440	Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors. 2020 , 2, 100170	23
439	Approach to the patient with acute severe autoimmune hepatitis. 2020 , 2, 100149	8
438	A possible increase in liver enzymes due to amlodipine: A case report. 2020 , 8, 2050313X20917822	2
437	Liver Injury in Critically Ill and Non-critically Ill COVID-19 Patients: A Multicenter, Retrospective, Observational Study. 2020 , 7, 347	17
436	Nilotinib-Induced Immune-Mediated Liver Injury: Corticosteroid as a Possible Therapeutic Option. 2020 , 10, 1160	1
435	Multidisciplinary Clinical Approach to Cancer Patients with Immune-Related Adverse Events Induced by Checkpoint Inhibitors. 2020 , 12,	6
434	Drug-induced liver injury after switching from tamoxifen to anastrozole in a patient with a history of breast cancer being treated for hypertension and diabetes. 2020 , 11, 2040622320964152	2

433	Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. 2020 , 5, 776-787	51
432	Drug-Induced Liver Injury in Liver Transplant Recipients: Informed Insights and Sage Advice From Andalusia. 2020 , 26, 1088-1089	
431	Metabolomics analysis of plasma reveals voriconazole-induced hepatotoxicity is associated with oxidative stress. 2020 , 403, 115157	2
430	Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological Basis. 2020 , 43, 1277-1285	13
429	Elastography improves accuracy of early hepato-biliary complications diagnosis after allogeneic stem cell transplantation. 2021 , 106, 2374-2383	5
428	Liver Failure. 2020,	1
427	Using advanced oxidation protein products and ischaemia-modified albumin to monitor oxidative stress levels in patients with drug-induced liver injury. 2020 , 10, 18128	10
426	Disulfiram-Induced Acute Liver Injury. 2020 , 2020, 8835647	O
425	Drug induced liver injury: an update. 2020 , 94, 3381-3407	40
424	Dietary Iron Overload Differentially Modulates Chemically-Induced Liver Injury in Rats. 2020 , 12,	3
423	Polygenic architecture informs potential vulnerability to drug-induced liver injury. 2020 , 26, 1541-1548	34
422	Possible role for acetylcysteine as a treatment for acute liver failure secondary to antitubercular medication use. 2020 , 77, 1482-1487	1
421	Severe drug-induced liver injury in patients under treatment with antipsychotic drugs: Data from the AMSP study. 2021 , 22, 373-386	2
420	Untargeted Metabolomics Reveals Anaerobic Glycolysis as a Novel Target of the Hepatotoxic Antidepressant Nefazodone. 2020 , 375, 239-246	2
419	Rituximab-induced autoimmune hepatitis: A case study and literature review. 2020 , 3, 381-386	1
418	Drug-induced liver injury in older people. 2020 , 5, 862-874	20
417	Graded doses of grape seed methanol extract attenuated hepato-toxicity following chronic carbamazepine treatment in male Wistar rats. 2020 , 7, 1592-1596	2
416	[Elevated liver enzymes]. 2020 , 162, 59-67	

(2020-2020)

415	Syndrome Coronavirus 2. 2020 , 13,	47
4 ¹ 4	Chronic autoimmune hepatitis triggered by olmesartan. 2020 , 43, 629-630	
413	Tu-San-Qi (Gynura japonica): the culprit behind pyrrolizidine alkaloid-induced liver injury in China. 2021 , 42, 1212-1222	15
412	When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report. 2020 , 8,	10
411	First case of drug-induced liver injury associated with the use of tocilizumab in a patient with COVID-19. 2020 , 40, 1901-1905	51
410	Role of liver biopsy in the era of clinical prediction scores for "drug-induced liver injury" (DILI): experience of a tertiary referral hospital. 2020 , 477, 517-525	2
409	Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults. <i>Journal of Hepatology</i> , 2020 , 73, 651-663	17
408	Clinical Characteristics of COVID-19 in Patients With Liver Injury. 2020 , 18, 2846-2847	7
407	The Influence of Chronic Liver Diseases on Hepatic Vasculature: A Liver-on-a-chip Review. 2020 , 11,	10
406	Drug-Induced Liver Injury and COVID-19 Infection: The Rules Remain the Same. 2020 , 43, 615-617	46
405	Prevalence, incidence and risk factors of tamoxifen-related non-alcoholic fatty liver disease: A systematic review and meta-analysis. 2020 , 40, 1344-1355	5
404	Critical role of OX40 in drug-induced acute liver injury. 2020 , 177, 3183-3196	2
403	Steroids as rescue therapy for vitamin A-induced acute liver failure. 2020 , 13,	3
402	Liver Enzyme Elevation in Coronavirus Disease 2019: A Multicenter, Retrospective, Cross-Sectional Study. 2020 , 115, 1075-1083	31
401	Liver involvement is not associated with mortality: results from a large cohort of SARS-CoV-2-positive patients. 2020 , 52, 1060-1068	34
400	Chemotherapy-associated steatohepatitis. 2020 , 19, 597-601	24
399	Metamizole: An underrated agent causing severe idiosyncratic drug-induced liver injury. 2020 , 86, 1406-1415	11
398	Art of Making Artificial Liver: Depicting Human Liver Biology and Diseases in Mice. 2020 , 40, 189-212	11

397	Recent advances in understanding the hepatotoxicity associated with protein kinase inhibitors. 2020 , 16, 217-226	5
396	Defining appropriate utilization of AST testing. 2020 , 79, 75-77	7
395	Molecular Biomarkers in Drug-Induced Liver Injury: Challenges and Future Perspectives. 2019 , 10, 1667	30
394	Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies. 2020 , 55, 653-661	14
393	NAFLD and autoimmune hepatitis: Do not judge a book by its cover. 2020 , 75, 1-9	12
392	Drug-induced liver injury associated with the biosimilar glatiramer acetate (Clift[]). 2020 , 40, 101948	2
391	Systematic review: ibuprofen-induced liver injury. 2020 , 51, 603-611	14
390	Drug-Induced Liver Injury in GI Practice. 2020 , 4, 631-645	20
389	COVID-19 in a designated infectious diseases hospital outside Hubei Province, China. 2020 , 75, 1742-1752	308
388	Drug-induced liver injury in pregnancy. 2020 , 68, 32-43	6
387	Causality assessment of skyfruit-induced liver injury using the updated RUCAM: a case report and review of the literature. 2020 , 48, 300060520917569	4
386	COVID-19: Abnormal liver function tests. <i>Journal of Hepatology</i> , 2020 , 73, 566-574	453
385	The complexity of T cell-mediated penicillin hypersensitivity reactions. 2021 , 76, 150-167	2
384	A High Serum Level of Taurocholic Acid Is Correlated With the Severity and Resolution of Drug-induced Liver Injury. 2021 , 19, 1009-1019.e11	5
383	Serious adverse events with tocilizumab: Pharmacovigilance as an aid to prioritize monitoring in COVID-19. 2021 , 87, 1533-1540	22
382	Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis. 2021 , 44, 133-165	4
381	A Case of Liver Injury after Exposure to Isopropanol: A Challenging Diagnosis. 2021 , 28, 198-201	
3 80	Multikinase inhibitor-induced liver injury in patients with cancer: A review for clinicians. 2021 , 157, 103127	1

(2021-2021)

379	Acute liver injury following turmeric use in Tuscany: An analysis of the Italian Phytovigilance database and systematic review of case reports. 2021 , 87, 741-753		13
378	Pazopanib-induced mixed liver injury in a patient with soft-tissue sarcoma, but without the UGT1A1*28 mutation: a case report. 2021 , 14, 224-228		1
377	Biomarkers of drug-induced liver injury: a mechanistic perspective through acetaminophen hepatotoxicity. 2021 , 15, 363-375		5
376	Empirical assessment of case-based methods for identification of drugs associated with acute liver injury in the French National Healthcare System database (SNDS). 2021 , 30, 320-333		
375	Clinical Characteristics and Outcome of Drug-Induced Liver Injury in the Older Patients: From the Young-Old to the Oldest-Old. 2021 , 109, 1147-1158		5
374	Intestinal Dysbiosis Amplifies Acetaminophen-Induced Acute Liver Injury. 2021, 11, 909-933		18
373	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021 , 74, 1097-1108	13.4	41
372	Transition to decompensation and acute-on-chronic liver failure: Role of predisposing factors and precipitating events. <i>Journal of Hepatology</i> , 2021 , 75 Suppl 1, S36-S48	13.4	3
371	Rooibos, a fake friend. 2021 , 45, 101499		2
370	The Effect of Curcumin Supplementation on Pulse Wave Velocity in Patients with Metabolic Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. 2021 , 1308, 1-11		4
369	Cholestatic liver disease: Practice guidelines from the Saudi Association for the Study of Liver diseases and Transplantation. 2021 , 27, 1		0
368	ANALYSIS OF THE STUDY OF 2% LIDOCAINE HYDROCHLORIDE SOLUTION HEPATOTOXICITY AT VARIOUS NUMBER OF INJECTIONS IN THE EXPERIMENT. 2021 , 2, 320		
367	Drug-Induced Liver Injury in Older Adults. 2021 , 1391-1406		
366	Clinical and genetic risk factors for the prediction of hepatotoxicity induced by a docetaxel, epirubicin and cyclophosphamide regimen in breast cancer patients. 2021 , 22, 87-98		2
365	High Serum Estradiol Reduces Acute Hepatotoxicity Risk Induced by Epirubicin Plus Cyclophosphamide Chemotherapy in Premenopausal Women with Breast Cancer. 2020 , 11, 572444		1
364	High-dose methotrexate-induced reversible grade 4 hyperbilirubinaemia and transaminitis in an adolescent with Burkitt Leukaemia. 2021 , 14,		1
363	Rutaecarpine Protects against Acetaminophen-Induced Acute Liver Injury in Mice by Activating Antioxidant Enzymes. 2021 , 10,		5
362	Leber. 2021 , 443-582		

Plant extracts with putative hepatotoxicity activity. **2021**, 259-287

360	Liver injury during rivaroxaban treatment in a patient with AL amyloidosis. 2021 , 77, 1073-1076	1
359	Herb-induced autoimmune-like hepatitis associated with Xiang-tian-guo (Swietenia macrophylla seeds): A case report and literature review. 2021 , 100, e24045	2
358	Updates on current biomarkers in toxicology. 2021 , 191-204	
357	Drug-induced peripheral oedema: An aetiology-based review. 2021 , 87, 3043-3055	5
356	Pharmacokinetics and safety of pegylated recombinant human granulocyte colony-stimulating factor in children with acute leukaemia. 2021 , 87, 3292-3300	1
355	Too Much of a Good Thing: Defining Antimicrobial Therapeutic Targets to Minimize Toxicity. 2021 , 109, 905-917	2
354	Drug-induced liver injury. 2021 , 193, E310	O
353	Cannabis use and reduced risk of elevated fatty liver index in HIV-HCV co-infected patients: a longitudinal analysis (ANRS CO13 HEPAVIH). 2021 , 19, 1147-1156	1
352	Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines. 2021 , 15, 258-282	15
351	Prevention and management of idiosyncratic drug-induced liver injury: Systematic review and meta-analysis of randomised clinical trials. 2021 , 164, 105404	9
350	Mitochondrial Dysfunction and Oxidative Stress in Liver Transplantation and Underlying Diseases: New Insights and Therapeutics. 2021 , 105, 2362-2373	4
349	Drug-induced liver injury associated with acenocumarol exposure. 2021 , 37, 120-123	О
348	Superoxide Dismutase Administration: A Review of Proposed Human Uses. 2021 , 26,	17
347	Network Pharmacology and Pharmacological Evaluation Reveals the Mechanism of the in Suppressing Hepatocellular Carcinoma. 2021 , 12, 618522	4
346	Oxidative Stress in Drug-Induced Liver Injury (DILI): From Mechanisms to Biomarkers for Use in Clinical Practice. 2021 , 10,	11
345	Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials. 2021 , 44, 619-634	2
344	Alcoholic liver disease and autoimmune hepatitis: Sometimes a closer look under the surface is needed. 2021 , 85, 86-91	3

(2021-2021)

343	Drug properties and host factors contribute to biochemical presentation of drug-induced liver injury: a prediction model from a machine learning approach. 2021 , 95, 1793-1803	2
342	Congenital dyserythropoietic anemia and drug-induced liver injury present as bland cholestasis: A case report. 2021 , 21, 456	1
341	Drug-induced liver injury in the era of biologics: The case of natalizumab.	0
340	Chronic Drug-Induced Liver Injury: Updates and Future Challenges. 2021 , 12, 627133	6
339	Metallothioneins alter macrophage phenotype and represent novel therapeutic targets for acetaminophen-induced liver injury. 2021 ,	Ο
338	Is COVID-19-induced liver injury different from other RNA viruses??. 2021 , 9, 108-127	
337	Challenges for Deriving Hepatocyte-Like Cells from Umbilical Cord Mesenchymal Stem Cells for In Vitro Toxicology Applications.	
336	Gastrointestinal and liver immune-related adverse effects induced by immune checkpoint inhibitors: A descriptive observational study. 2021 , 44, 261-268	O
335	Pharmacokinetics, toxicological and clinical aspects of ulipristal acetate: insights into the mechanisms implicated in the hepatic toxicity. 2021 , 53, 375-383	2
334	Hepatic manifestations of drug reaction with eosinophilia and systemic symptoms syndrome.	
221		
333	Immune-Mediated Drug-Induced Liver Injury: Immunogenetics and Experimental Models. 2021 , 22,	6
		6
333	Immune-Mediated Drug-Induced Liver Injury: Immunogenetics and Experimental Models. 2021 , 22,	
333	Immune-Mediated Drug-Induced Liver Injury: Immunogenetics and Experimental Models. 2021 , 22, Safety considerations for the management of cholestatic itch. 2021 , 20, 915-924	0
333 332 331	Immune-Mediated Drug-Induced Liver Injury: Immunogenetics and Experimental Models. 2021, 22, Safety considerations for the management of cholestatic itch. 2021, 20, 915-924 Prednisolone: role in amoxicillin-clavulanate-induced cholestatic liver injury. 2021, 14,	0
333 332 331 330	Immune-Mediated Drug-Induced Liver Injury: Immunogenetics and Experimental Models. 2021, 22, Safety considerations for the management of cholestatic itch. 2021, 20, 915-924 Prednisolone: role in amoxicillin-clavulanate-induced cholestatic liver injury. 2021, 14, Mixed steatohepatitis: more questions than answers (part 2). 2021, 93, 516-520	0
333 332 331 330 329	Immune-Mediated Drug-Induced Liver Injury: Immunogenetics and Experimental Models. 2021, 22, Safety considerations for the management of cholestatic itch. 2021, 20, 915-924 Prednisolone: role in amoxicillin-clavulanate-induced cholestatic liver injury. 2021, 14, Mixed steatohepatitis: more questions than answers (part 2). 2021, 93, 516-520 Squaramide-Based Supramolecular Materials Drive HepG2 Spheroid Differentiation. 2021, 10, e2001903 Gastrointestinal and liver immune-related adverse effects induced by immune checkpoint	o 1

325	Zanubrutinib-induced liver injury: a case report and literature review. 2021 , 21, 244	6
324	Movement Disorders and Liver Disease. 2021 , 8, 828-842	2
323	Case report: Secondary sclerosing cholangitis induced by lapatinib and vinorelbine in a metastasis breast cancer patient. 2021 , 12, 1912-1916	1
322	Hepatotoxicity reports in the FDA adverse event reporting system database: A comparison of drugs that cause injury mitochondrial or other mechanisms 2021 , 11, 3857-3868	3
321	Clinical management of patients with drug-induced liver injury (DILI). 2021, 9, 781-786	2
320	Evaluation of liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy. 2021 , 16, e0253070	2
319	Current and Past Infections of HBV Do Not Increase Mortality in Patients With COVID-19. 2021, 74, 1750-1765	5 12
318	Ibuprofen induced Stevens-Johnson syndrome and liver injury in children: a case report. 2021 , 10, 1737-1742	O
317	Autoimmune hepatitis following COVID-19 vaccination: True causality or mere association?. <i>Journal of Hepatology</i> , 2021 , 75, 1250-1252	25
316	Clinical course and outcomes of COVID-19 patients with a history of cerebrovascular disease: a retrospective study in Wuhan. 2021 , 9, 988	1
315	Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment. 2021 , 27, 2994-3009	38
314	Drug-induced liver injury in Australia, 2009-2020: the increasing proportion of non-paracetamol cases linked with herbal and dietary supplements. 2021 , 215, 261-268	3
313	Use of N-Acetylcysteine for Clozapine-Induced Acute Liver Injury: A Case Report and Literature Review. 2021 , 8971900211034007	2
312	Drug-induced liver injury at a tertiary care centre in Germany: Model for end-stage liver disease is the best predictor of outcome. 2021 , 41, 2383-2395	O
311	Safety of treating acute liver injury and failure. 2021 , 1-13	2
310	Drug-induced liver injury associated with severe cutaneous adverse drug reactions: A nationwide study in Taiwan. 2021 , 41, 2671-2680	2
309	The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review. 2021 , 35, 861-880	3
308	Clinical Course and Treatment Implications of Combination Immune Checkpoint Inhibitor-Mediated Hepatitis: A Multicentre Cohort 2022 , 5, 39-47	2

307	The microbiota in cirrhosis and its role in hepatic decompensation. <i>Journal of Hepatology</i> , 2021 , 75 Suppl 1, S67-S81	23
306	Risk Factors for Hepatotoxicity Due to Paracetamol Overdose in Adults. 2021 , 57,	О
305	Inhibition of Drug-Induced Liver Injury in Mice Using a Positively Charged Peptide That Binds DNA. 2021 , 5, 1737-1754	1
304	Herb-induced liver injury: Systematic review and meta-analysis. 2021 , 9, 5490-5513	4
303	Liver injury associated with drug intake during pregnancy. 2021 , 13, 747-762	1
302	Circulatory Inflammatory Mediators in the Prediction of Anti-Tuberculous Drug-Induced Liver Injury Using RUCAM for Causality Assessment. 2021 , 9,	2
301	Guideline review: EASL clinical practice guidelines: drug-induced liver injury (DILI). flgastro-2021-101886	4
300	Managing abnormal liver tests in children with inflammatory bowel disease. 2021 , 33, 521-529	1
299	Characteristics and outcomes of patients with COVID-19 and liver injury: a retrospective analysis and a multicenter experience. 2021 ,	1
298	An unusual case of acute cholestatic hepatitis after m-RNABNT162b2 (Comirnaty) SARS-CoV-2 vaccine: Coincidence, autoimmunity or drug-related liver injury. <i>Journal of Hepatology</i> , 2021 , 75, 1254-12564	15
297	A case of self-limited drug induced liver injury under treatment with elexacaftor/tezacaftor/ivacaftor: When it is worth taking the risk. 2021 , 20, 712-714	1
296	Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry. <i>Journal of Hepatology</i> , 2021 , 75, 86-97	18
295	A Multi-Omics Human Liver Organoid Screening Platform for DILI Risk Prediction.	0
294	Deciphering the Dynamic Complexities of the Liver Microenvironment - Toward a Better Understanding of Immune-Mediated liver Injury Caused by Immune Checkpoint Inhibitors (ILICI). 2021 , 23, 99	
293	The Diagnosis of Drug-induced Liver Injury: Current Diagnostic Ability and Future Challenges of the Digestive Disease Week-Japan 2004 Scale 15 Years after Its Proposal. 2021 , 60, 2557-2568	1
292	High Risk of Viral Reactivation in Hepatitis B Patients with Systemic Lupus Erythematosus. 2021 , 22,	Ο
291	Synthesis, anticancer evaluation, CDK2 inhibition, and apoptotic activity assessment with molecular docking modeling of new class of pyrazolo[1,5-a]pyrimidines. 1	2
290	Protecting mitochondria via inhibiting VDAC1 oligomerization alleviates ferroptosis in acetaminophen-induced acute liver injury. 2021 , 1	6

289	Acute liver failure in Still's disease relapse during pregnancy: case report and discussion of a possible trigger role of DILI. 2021 , 21, 317	1
288	The LAC Score Indicates Significant Fibrosis in Patients With Chronic Drug-Induced Liver Injury: A Large Biopsy-Based Study. 2021 , 12, 734090	2
287	Aseptic meningitis, hepatitis and cholestasis induced by trimethoprim/sulfamethoxazole: a case report. 2021 , 21, 345	1
286	A medicinal liver injury with an immunomodulatory drug of natural origin. Case report. 2021 , 93, 932-935	Ο
285	Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignancies. 2021 , 15, 1278-1287	4
284	Pancreatic damage in COVID-19: Why? How?. 2021 , 75, e14692	2
283	Immune checkpoint inhibitor-related hepatotoxicity: A review. 2021 , 27, 5376-5391	10
282	Research status and progress of drug induced liver injury. 2021 , 29, 915-925	Ο
281	Knowledge of Herbal Medicines - Is a Reverse Bridge Course an Urgent Necessity?. 2022 , 12, 249-251	Ο
280	A Retrospective Cohort Study: Safety and Effectiveness of Elbasvir/Grazoprevir – Ribavirin Compared With Ombitasvir/Paritaprevir/Ritonavir/Dasabuvir – Ribavirin in Patients With Chronic Hepatitis C Genotype 1 Infection. 2021 , 12, 640317	Ο
279	Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management. 2021 ,	2
278	Hydrochlorothiazide-induced hepatotoxicity: A rare case of DILI. 2021 , 45, 101599	1
277	A Multiple Logistic Regression Model Based on Gamma-Glutamyl Transferase as a Biomarker for Early Prediction of Drug-Induced Liver Injury in Vietnamese Patients. 2021 ,	
276	Herb-Induced Liver Injury Related to (Thunb.) Moldenke: Risk Factors, Molecular and Mechanistic Specifics. 2021 , 12, 738577	1
275	Research Progress of Pharmacogenomics in Drug-Induced Liver Injury. 2021 , 12, 735260	1
274	Drug-induced liver injury: A management position paper from the Latin American Association for Study of the liver. 2021 , 24, 100321	3
273	Hugan tablets for the treatment of RUCAM based drug-induced liver injury: a propensity score matching analysis using a nationwide database. 2021 , 1-8	0
272	Clozapine-induced hepatotoxicity: A life threatening situation. 2021 , 235, 3-4	Ο

271	Palbociclib-induced severe hepatitis: A case study and literature review. e20210015	1
270	Overview on drug-induced liver injury in Brazil. 2021 , 12, 100-102	
269	Elevation of Serum Transaminase Levels Due to Favipiravir Use in the Treatment of COVID-19. 2021 , 13, e18166	O
268	Rash and cholestatic liver injury caused by methimazole in a woman with Turner syndrome and Graves's disease: a case report and literature review. 2021 , 21, 179	1
267	Safety and disease monitoring biomarkers in Duchenne muscular dystrophy: results from a Phase II trial. 2021 , 15, 1389-1396	0
266	Signal Detection of Potential Hepatotoxic Drugs: Case-Control Study Using Both a Spontaneous Reporting System and Electronic Medical Records. 2021 , 44, 1514-1523	O
265	Pharmacodynamics and pharmacokinetics of a copper intrauterine contraceptive system releasing ulipristal acetate: A randomized proof-of-concept study. 2021 , 104, 327-336	1
264	Late hepatic toxicity surveillance for survivors of childhood, adolescent and young adult cancer: Recommendations from the international late effects of childhood cancer guideline harmonization group. 2021 , 100, 102296	1
263	Toxische Lebererkrankungen. 2021 , 346-355	
262	Alcohol-associated liver disease: A review on its pathophysiology, diagnosis and drug therapy. 2021 , 8, 376-385	5
261	Impact of genetic and environmental factors on autoimmune hepatitis. 2021 , 4, 100125	1
260	Drug-Induced Liver Injury. 2021 ,	
259	Advancements in stem cell-derived hepatocyte-like cell models for hepatotoxicity testing. 2021, 12, 84	11
258	Drug-Induced Liver Injury in Older Adults. 2020 , 1-16	1
257	Chronic autoimmune hepatitis triggered by olmesartan. 2020 , 43, 629-630	О
256	Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience. 2020 , 20, 1047-1059	3
255	Hepatotoxicity of FDA-approved small molecule kinase inhibitors. 2021 , 20, 335-348	4
254	A pilot study to investigate the utility of NAT2 genotype-guided isoniazid monotherapy regimens in NAT2 slow acetylators. 2021 , 31, 68-73	5

253	Drug-induced liver injury. 2020 , 37, 2-12	11
252	Drug Liver Injury Induced by Olmesartan Mediated by Autoimmune-Like Mechanism: A Case Report. 2020 , 7, 001407	2
251	Hypertransaminasemia in the course of infection with SARS-CoV-2: Incidence and pathogenetic hypothesis. 2020 , 8, 1385-1390	18
250	Flucloxacillin-Induced Hepatotoxicity - Association with HLA-B*5701. 2020 , 66, 12-17	7
249	Acute hepatitis due to olmesartan: an uncommon entity. 2021 , 113, 223-224	2
248	Acute hepatocellular drug-induced liver injury probably caused by doxazosin. 2021, 113, 301-302	2
247	Drug-Induced liver Injury Associated with Severe Cutaneous Hypersensitivity Reactions: A Complex Entity in Need of a Multidisciplinary Approach. 2019 , 25, 3855-3871	8
246	A Rare Case of Acute Generalized Exanthematous Pustulosis with Drug-Induced Liver Injury caused by Pyrazinamide. 2020 , 12, 54-58	1
245	Drug-Induced Fatty Liver Disease. 2020 , 8, 66-76	4
244	Antineoplastic drugs and drug-induced liver damage with cholestasis. 2020 , 1, 47-54	4
243	Drug-induced liver damage with cholestasis. 2020 , 61-74	3
242	Estanozolol como anablico: una causa de hepatotoxicidad. 2021 , 40, 75-79	
242	Estanozolol como anablico: una causa de hepatotoxicidad. 2021 , 40, 75-79 Development and validation of a prognostic model for leflunomide discontinuation with abnormal blood-tests during long-term treatment: cohort study using data from Clinical Practice Research Datalink Gold and Aurum. 2021 ,	
	Development and validation of a prognostic model for leflunomide discontinuation with abnormal blood-tests during long-term treatment: cohort study using data from Clinical Practice Research	1
241	Development and validation of a prognostic model for leflunomide discontinuation with abnormal blood-tests during long-term treatment: cohort study using data from Clinical Practice Research Datalink Gold and Aurum. 2021, Differential Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor	1
241	Development and validation of a prognostic model for leflunomide discontinuation with abnormal blood-tests during long-term treatment: cohort study using data from Clinical Practice Research Datalink Gold and Aurum. 2021, Differential Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on COVID-19. 2021, 3, 10 The Unmet Needs of Hepatitis E Virus Diagnosis in Suspected Drug-Induced Liver Injury in Limited	
241 240 239	Development and validation of a prognostic model for leflunomide discontinuation with abnormal blood-tests during long-term treatment: cohort study using data from Clinical Practice Research Datalink Gold and Aurum. 2021, Differential Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on COVID-19. 2021, 3, 10 The Unmet Needs of Hepatitis E Virus Diagnosis in Suspected Drug-Induced Liver Injury in Limited Resource Setting. 2021, 12, 737486 Role of Ursodeoxycholic Acid in Treating and Preventing Idiosyncratic Drug-Induced Liver Injury. A	0

235	Long-term sequelae of drug-induced liver injury. Journal of Hepatology, 2021,	13.4	1
234	Machine Learning to Identify Interaction of Single-Nucleotide Polymorphisms as a Risk Factor for Chronic Drug-Induced Liver Injury. 2021 , 18,		O
233	The Immunological Mechanisms and Immune-Based Biomarkers of Drug-Induced Liver Injury. 2021 , 12, 723940		5
232	Primary esophageal malignant melanoma with severe liver injury of immune-related adverse events caused by nivolumab. 2021 , 62, 630-638		О
231	Immune-related Liver Injury is a Poor Prognostic Factor in Patients with Nonsmall Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. 2021 , 1-10		1
230	Drug Induced Liver Injury. 2022 , 411-442		
229	Clinical characteristics and outcomes of drug-induced liver injury in Taiwan with an emphasis on the impact of chronic hepatitis B infection. 2021 ,		O
228	Incidence of adverse reaction of drugs used in COVID-19 management: a retrospective, observational study. 2021 , 14, 84		2
227	Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAF mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trial. 2021 , 158, 72-84	1	3
226	Anti-Tuberculosis Drug Induced Liver Injury and Ursodeoxycholic Acid. 2020 , 08, 66-72		
225	Noninvasive assessment of liver fibrosis in Crohn's disease patients exposed to methotrexate. 2021 , 33, 794-798		1
224	Common Gastrointestinal Medications Implicated in Drug-Induced Liver Injury. 2021 , 18, 184-188		
223	Tuberculosis treatment spills the beans on Wilson⊞ disease and more. 2021,		
222	The Therapeutic Principle of Combined Strengthening Qi and Eliminating Pathogens in Treating Middle-Advanced Primary Liver Cancer: A Systematic Review and Meta-Analysis. 2021 , 12, 714287		1
221	Membrane-delimited signaling and cytosolic action of MG53 preserve hepatocyte integrity during drug-induced liver injury. <i>Journal of Hepatology</i> , 2021 ,	13.4	2
220	Safety of Herbal Medicines: Clinical and Pharmacological Aspects. 2020 , 8, 165-177		3
219	Bacteremia-Induced Cholestatic Jaundice as a Major Manifestation of Pneumococcal Infection in a Healthy Toddler. 2021 , 16, 085-088		
218	Vedolizumab-Induced Liver Injury 2021 , 28, 410-415		

217	Correction possibilities of drug-induced liver toxicity in the treatment of patients with blood system tumors. 2020 , 15, 65-81	
216	ResNet18DNN: prediction approach of drug-induced liver injury by deep neural network with ResNet18. 2021 ,	O
215	Drug-Induced Acute and Acute on Chronic Liver Failure. 2020 , 219-232	
214	Safety of Korean Medicine Treatment in Patients Vaccinated with the AstraZeneca COVID-19 Vaccine (ChAdOx1 nCoV-19/AZD1222): A Case Series. 2021 , 42, 590-604	О
213	Biomarkers of idiosyncratic drug-induced liver injury (DILI) - a systematic review. 2021 , 17, 1327-1343	1
212	Embarazo y lesifi hepfica inducida por medicamentos. Reporte de un caso y revisifi de la literatura. 2020, 157-164	
211	Drug-induced liver injury in cancer patients. 2020 , 15, 80-94	
2 10	Drug-induced liver injuries in practice of primary care physician (review of clinical recommendations). 2020 , 58-69	1
209	Aripiprazole reduces liver cell division. 2020 , 15, e0240754	1
208	Influence of the Acetylation Type on the Incidence of Isoniazid-Induced Hepatotoxicity in Patients with Newly Diagnosed Pulmonary Tuberculosis. 2020 , 65, 31-36	
207	Vedolizumab-induced cholestatic liver injury. 2020 , 45, 64-64	0
206	[Consensus of Chinese experts on prevention and standardized treatment of drug-induced liver injury in patients with blood diseases (2021)]. 2021 , 42, 185-192	
205	Adverse events associated with analgesics: A focus on paracetamol use. 2022 , 309-317	О
204	Hepatotoxicity of metronidazole in Cockayne syndrome: A clinical report. 2021 , 65, 104388	3
203	Critical Review of Gaps in the Diagnosis and Management of Drug-Induced Liver Injury Associated with Severe Cutaneous Adverse Reactions. 2021 , 10,	1
202	Drug Induced Liver Injury: Perspective of the Adverse Drug Reaction Reports to the Portuguese Pharmacovigilance System from 2010 to 2019 2021 , 9,	O
201	Drug-induced liver injury: Pathogenesis, epidemiology, clinical features, and practical management. 2021 ,	2
200	Protective effect of aqueous leaf extracts of and on doxorubicin-induced hepatotoxicity in Wistar rats. 2021 , 6, e143	O

199	Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction 2021 , 11, 3685-3726	3
198	Role of immune dysfunction in drug induced liver injury 2021 , 13, 1677-1687	O
197	Colchicine Effectiveness and Safety in Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenitis 2021 , 9, 759664	O
196	Klinisches Management von Patienten mit Leberzirrhose. 2021 , 2, 119	
195	The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. 2021 ,	12
194	Drugs and Toxins Affecting Liver Vessels. 2022 , 345-363	
193	Menotrophin induced autoimmune hepatitis: a case report. 2019 , 10, 164-166	
192	Drug-induced liver injury: What a dermatologist should know?. 2021 , 7, 106	
191	Effects of omega-3 and vitamin c on methotrexate-induced liver injury. 2021 , 20, 39	
190	The Effects of Curcumin Plus Piperine Supplementation in Patients with Acute Myocardial Infarction: A Randomized, Double-Blind, and Placebo-Controlled Trial 2021 , 1328, 199-211	1
189	Impact of Liver Functions by Repurposed Drugs for COVID-19 Treatment. 2022 , 000, 000-000	1
188	Prediction of Biochemical Nonresolution in Patients with Chronic Drug-induced Liver Injury: A Large Multicenter Study 2021 ,	2
187	HepG2-NIAS cells, a new subline of HepG2 cells that can enhance not only CYP3A4 activity but also expression of drug transporters and form bile canaliculus-like networks by the oxygenation culture via a collagen vitrigel membrane 2022 , 47, 39-50	О
186	Characteristics of peripheral blood Gamma-glutamyl transferase in different liver diseases 2022 , 101, e28443	O
185	A Revised Electronic Version of RUCAM for the Diagnosis of Drug Induced Liver Injury 2022,	9
184	Severe Persistent Jaundice after the Abuse of an Anabolic Androgenic Steroid Analogue. 2020 , 76, 167-170	O
183	Hepatotoxicity Caused By Phenyramidol Hydrochloride: A Case Report.	
182	Liver Injury in Patients Hospitalized for COVID-19: Possible Role of Therapy 2022 , 10,	2

181	Pharmacotherapies for Drug-Induced Liver Injury: A Current Literature Review 2021 , 12, 806249	5
180	Herb-Induced Liver Injury-A Challenging Diagnosis 2022 , 10,	1
179	Immunotherapy and Gene Therapy: New Challenges in the Diagnosis and Management of Drug-Induced Liver Injury 2021 , 12, 786174	O
178	Drug-induced liver injury from herbal and dietary supplements: a problem in the East and West alike 2022 , 1	
177	Detailed Molecular Mechanisms Involved in Drug-Induced Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: An Update 2022 , 10,	2
176	Prediction of Biochemical Nonresolution in Patients with Chronic Drug-induced Liver Injury: A Large Multicenter Study 2022 ,	
175	The therapeutic potential of exosomes derived from different cell sources in liver diseases 2022,	O
174	Novel Therapies for the Treatment of Drug-Induced Liver Injury: A Systematic Review 2021 , 12, 785790	3
173	Dissecting the Crosstalk Between Nrf2 and NF-B Response Pathways in Drug-Induced Toxicity 2021 , 9, 809952	6
172	Harnessing reactive oxygen/nitrogen species and inflammation: Nanodrugs for liver injury 2022 , 13, 100215	4
171	Vedolizumab-induced cholestatic liver injury. 2022 , 45, 64-65	
170	Acute liver failure 2022 , 28,	1
169	Severe tyrosine-kinase inhibitor induced liver injury in metastatic renal cell carcinoma patients: two case reports assessed for causality using the updated RUCAM and review of the literature 2022 , 22, 49	3
168	Effectiveness of Integrative Chinese-Western Medicine for Chronic Kidney Disease and Diabetes: A Retrospective Cohort Study 2022 , 1-18	1
167	The Correlated Risk Factors for Severe Liver Damage Among HIV-Positive Inpatients With Abnormal Liver Tests 2022 , 9, 817370	
166	Letter to the editor: RECAM for the diagnosis of DILI-Is it time to incorporate additional pharmacological criteria?. 2022 ,	
165	New Perspectives to Improve Mesenchymal Stem Cell Therapies for Drug-Induced Liver Injury 2022 , 23,	1
164	2022,	O

163	Drug-Induced Liver Injury during Consolidation Therapy in Childhood Acute Lymphoblastic Leukemia as Assessed for Causality Using the Updated RUCAM 2022 , 2022, 5914593	1
162	Acute Liver Failure following a Single Dose of Atezolizumab, as Assessed for Causality Using the Updated RUCAM 2022 , 2022, 5090200	
161	Da⊞o hepEico inducido por medicamentos: relaciE entre el Eldice R y la histopatologE. 2022 ,	
160	Glucocorticoid Treatment Strategies in Liver Failure 2022 , 13, 846091	O
159	Evaluating the Impact of a Risk Evaluation and Mitigation Strategy With Tolvaptan to Monitor Liver Safety in Patients with Autosomal Dominant Polycystic Kidney Disease.	O
158	Corticosteroid plus glycyrrhizin therapy for chronic drug- or herb-induced liver injury achieves biochemical and histological improvements: A randomised open-label trial 2022 ,	0
157	Amlodipine-Induced Liver Injury 2022 , 14, e23441	
156	A novel phenotype-based drug-induced liver injury causality assessment tool (DILI-CAT) allows for signal confirmation in early drug development 2022 ,	2
155	Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition) 2022 , 11, 227-252	0
154	Incidence and risk factors of drug-induced liver injury 2022,	O
153	Specificities of lipotoxicity of free fatty acids and cytokine profile in patients with chronic diffuse liver diseases. 2022 , 13, 3-9	
152	Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients. 2021 , 148, 647	2
151	Drug-Induced Liver Injury Induced by Bioflavonoids 2021 , 13, e20453	0
150	Not your usual drug-drug interactions: Monoclonal antibody-based therapeutics may interact with antiseizure medications 2021 ,	1
149	Insight into microRNAs-Mediated Communication between Liver and Brain: A Possible Approach for Understanding Acute Liver Failure?. 2021 , 23,	0
148	Which NSAID to choose for treatment of pain syndrome in polymorbid patients?. 2021 , 41-46	
147	Drug-induced liver injury by glecaprevir/pibrentasvir treatment for chronic hepatitis C infection: a systematic review and meta-analysis 2022 , 54, 108-120	1
146	Targeted Metabolomics Analysis of Bile Acids in Patients with Idiosyncratic Drug-Induced Liver Injury 2021 , 11,	Ο

145	ਬੋnl−urfa YEesi Etoksikasyon Olgular− ve Karaciër Toksisitesinin Deਬrlendirilmesi. 456-459	
144	Analysis of Clinical Characteristics and Chronic Factors of Drug-induced Liver Injury in Chronic Hepatitis B Infection: A Retrospective Study. 2021 , 21,	
143	Liver-side of inflammatory bowel diseases: Hepatobiliary and drug-induced disorders 2021 , 13, 1828-1849	1
142	Population Pharmacokinetics and Pharmacodynamic Target Attainment of Isavuconazole against and in Adult Patients with Invasive Fungal Diseases: Should Therapeutic Drug Monitoring for Isavuconazole Be Considered as Mandatory as for the Other Mold-Active Azoles?. 2021 , 13,	1
141	A case report of drug-induced liver injury after tigecycline administration: histopathological evidence and a probable causality grading as assessed by the updated RUCAM diagnostic scale 2022 , 22, 368	1
140	Evaluation and Assessment of the Acute Toxic Potential of <i>Sansevieria cylindrica</i> and </i>Plumeria obtusa</i> Plant Extracts in Wistar Albino Rats. 2022 , 22, 209	
139	Severe Hepatocellular Liver Injury After COVID-19 Vaccination Without Autoimmune Hepatitis Features: A Case Series. 2022 , 9, e00760	O
138	Fraxinellone Induces Hepatotoxicity in Zebrafish through Oxidative Stress and the Transporters Pathway 2022 , 27,	O
137	Prevalence and risk factors of tigecycline-induced liver injury: A multicenter retrospective study 2022 ,	1
136	Data_Sheet_1.docx. 2020,	
136	Data_Sheet_1.docx. 2020, Hepatic Macrophage activation and the LPS pathway in patients with different degrees of severity and histopathological patterns of drug induced liver injury. 2021, 36, 653-662	1
	Hepatic Macrophage activation and the LPS pathway in patients with different degrees of severity	1
135	Hepatic Macrophage activation and the LPS pathway in patients with different degrees of severity and histopathological patterns of drug induced liver injury. 2021 , 36, 653-662	1
135	Hepatic Macrophage activation and the LPS pathway in patients with different degrees of severity and histopathological patterns of drug induced liver injury. 2021 , 36, 653-662 Diagnostic value of a liver biopsy in patients with an acute liver failure or acute liver injury 2022 ,	1
135 134 133	Hepatic Macrophage activation and the LPS pathway in patients with different degrees of severity and histopathological patterns of drug induced liver injury. 2021, 36, 653-662 Diagnostic value of a liver biopsy in patients with an acute liver failure or acute liver injury 2022, Herb-Induced Liver Injury: A Report on Two Australian Cases. 2022, Gut Microbiota Mediates the Therapeutic Effect of Monoclonal Anti-TLR4 Antibody on	
135 134 133	Hepatic Macrophage activation and the LPS pathway in patients with different degrees of severity and histopathological patterns of drug induced liver injury. 2021, 36, 653-662 Diagnostic value of a liver biopsy in patients with an acute liver failure or acute liver injury 2022, Herb-Induced Liver Injury: A Report on Two Australian Cases. 2022, Gut Microbiota Mediates the Therapeutic Effect of Monoclonal Anti-TLR4 Antibody on Acetaminophen-Induced Acute Liver Injury in Mice 2022, e0064722 Real-World Financial and Clinical Impact of Diagnostic-Driven and Empirical-Treatment Strategies in High-Risk Immunocompromised Patients with Suspected Aspergillus Infection in the United	
135 134 133 132	Hepatic Macrophage activation and the LPS pathway in patients with different degrees of severity and histopathological patterns of drug induced liver injury. 2021, 36, 653-662 Diagnostic value of a liver biopsy in patients with an acute liver failure or acute liver injury 2022, Herb-Induced Liver Injury: A Report on Two Australian Cases. 2022, Gut Microbiota Mediates the Therapeutic Effect of Monoclonal Anti-TLR4 Antibody on Acetaminophen-Induced Acute Liver Injury in Mice 2022, e0064722 Real-World Financial and Clinical Impact of Diagnostic-Driven and Empirical-Treatment Strategies in High-Risk Immunocompromised Patients with Suspected Aspergillus Infection in the United Kingdom 2022, e0042522 Clinical course and outcomes of COVID-19 patients with chronic obstructive pulmonary disease: A	1

127	Management of Pharmacologic Adverse Effects in Advanced Liver Disease 2022, 1		0
126	CROATIAN GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE 2021 , 60, 36-52		
125	Silymarin for Treating Toxic Liver Disease: International Consensus Recommendations. 2022,		1
124	Efficacy and safety of bicyclol for treating patients with idiosyncratic acute drug-induced liver injury: A multicenter, randomized, phase II trial 2022 ,		
123	N-Acetylcysteine for the Management of Non-Acetaminophen Drug-Induced Liver Injury in Adults: A Systematic Review. 2022 , 13,		1
122	Iberogast[] -Induced Acute Liver Injury[A Case Report. 2022 , 1, 601-603		O
121	Treatment of rheumatoid arthritis with conventional, targeted and biological disease-modifying antirheumatic drugs in the setting of liver injury and non-alcoholic fatty liver disease.		
120	Role of silymarin as antioxidant in clinical management of chronic liver diseases: a narrative review. 2022 , 54, 1548-1560		2
119	Liver Injury with Nintedanib: A Pharmacovigilance Pharmacokinetic Appraisal. 2022, 15, 645		0
118	A study to evaluate the hepatoprotective effect of N- acetylcysteine on anti tuberculosis drug induced hepatotoxicity and quality of life. 2022 ,		
117	Drug Induced Liver Injury in Pediatrics. Publish Ahead of Print,		
116	Hepatitis autoinmune: retos y novedades. 2022 ,		O
115	Effects of Anthraquinones on Immune Responses and Inflammatory Diseases. 2022, 27, 3831		1
114	Senna makki and other active phytochemicals: Myths and realities behind covid19 therapeutic interventions. 2022 , 17, e0268454		
113	Selected Liver Markers in Predicting the Severity of Organophosphate and Carbamate Poisoning. 2022 , 2022, 1-6		
112	The Incidence of Hepatitis E infection in American Patients with Suspected Drug-Induced Liver Injury is low and declining: The DILIN Prospective Study. 2022 , Publish Ahead of Print,		0
111	THE OVERWEIGHT AND OBESITY ROLE IN THE OCCURRENCE OF CHEMOTHERAPY-INDUCED HEPATOTOXIC REACTIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA. 2022 , 75, 1506-1511		
110	Risk of acute liver injury following the mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines. <i>Journal of Hepatology</i> , 2022 ,	13.4	2

109	The Dual Role of Innate Immune Response in Acetaminophen-Induced Liver Injury. 2022, 11, 1057	O
108	Sex disparity and drug-induced liver injury. 2022 ,	O
107	Itching to find a diagnosis.	0
106	Mitochondrial Dysfunction and Chronic Liver Disease. 2022 , 44, 3156-3165	3
105	Construction of Polysaccharide Scaffold-Based Perfusion Bioreactor Supporting Liver Cell Aggregates for Drug Screening. 1-21	
104	Clinical Significance of Transient Asymptomatic Elevations in Aminotransferase (TAEAT) in Oncology. Publish Ahead of Print,	1
103	Progress and Setbacks in Translating a Decade of Ferroptosis Research into Clinical Practice. 2022 , 11, 2134	1
102	RIPK1 in Liver Parenchymal Cells Limits Murine Hepatitis during Acute CCl4-Induced Liver Injury. 2022 , 23, 7367	
101	Microbiota diversity in nonalcoholic fatty liver disease and in drug-induced liver injury. 2022, 106348	1
100	Drug-Induced Liver Injury From Sacubitril-Valsartan Versus a Single Dose of Acarbose. 2022 ,	
99	A new framework for advancing in Drug-Induced Liver Injury research. The Prospective European DILI Registry.	1
98	Drug-Induced Hepatitis in Children: The Experience of a Single Center in Romania. 2022 , 9, 1136	
97	European guideline on obesity care in patients with gastrointestinal and liver diseases Doint ESPEN/UEG guideline. 2022 ,	4
96	Therapeutic Management of Idiosyncratic Drug-Induced Liver Injury and Acetaminophen Hepatotoxicity in the Paediatric Population: A Systematic Review.	O
95	The association of chiral characteristic with drug withdrawal due to safety: A comparative analysis.	
94	Strategies and Tools for Supporting the Appropriateness of Drug Use in Older People. 2022 , 15, 977	
93	A case of anti-programmed death-ligand 1 antibody-induced multisystem immune-related adverse events with pancreatitis and steroid-resistant sclerosing cholangitis.	0
92	Hepatitis aguda colest⊠ica secundaria a atorvastatina. 2022 ,	

91	Biohybrid response microparticles decorated with trained-MSCs for Acute Liver Failure Recovery. 2201085	1
90	Identifying Drug-Induced Liver Injury Associated With Inflammation-Drug and Drug-Drug Interactions in Pharmacologic Treatments for COVID-19 by Bioinformatics and System Biology Analyses: The Role of Pregnane X Receptor. 13,	O
89	Elevated serum gamma-glutamyl transferase is associated with low muscle function in adults independent of muscle mass. 2022 , 111813	1
88	Oncological-Therapy-Associated Liver Injuries.	
87	Evaluation of liver function tests to identify hepatotoxicity among acute lymphoblastic leukemia patients who are receiving chemotherapy induction. 2022 , 12,	
86	European guideline on obesity care in patients with gastrointestinal and liver diseases Doint European Society for Clinical Nutrition and Metabolism / United European Gastroenterology guideline.	1
85	Association between Adverse Events and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study. 2022 , 14, 4284	1
84	Incidence and Pattern of Aminotransferase Elevation During Anti-Hypertensive Therapy With Angiotensin-II Receptor Blockers. 2022 , 37,	1
83	Impact of pharmacist active consultation on clinical outcomes and quality of medical care in drug-induced liver injury inpatients in general hospital wards: A retrospective cohort study. 13,	O
82	Antibiotics enhancing drug-induced liver injury assessed for causality using Roussel Uclaf Causality Assessment Method: Emerging role of gut microbiota dysbiosis. 9,	1
81	Autoimmune Hepatitis with Acute Presentation: Clinical, Biochemical, and Histological Features of 126 Patients. 2022 , 2022, 1-9	О
80	Antipsychotic Safety in Liver Disease: A Narrative Review and Practical Guide for the Clinician. 2022,	1
79	Drug-induced liver injury associated with dacomitinib: A case report. 12,	О
78	Autoimmune hepatitis: Challenges and novelties. 2022 , 159, 289-298	O
77	Efficacy and safety of low-dose rifampicin in patients with benign intrahepatic cholestasis. 2022 , 6, 181-185	О
76	Leberfunktionsstflungen bei geriatrischen Patienten. 2022 , 55, 519-530	O
75	In Vitro Models for Studying Chronic Drug-Induced Liver Injury. 2022 , 23, 11428	1
74	Clinical Pattern of Tolvaptan-Associated Liver Injury in Trial Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD): An Analysis of Pivotal Clinical Trials. 2022 ,	1

73	Herb-induced hepatitis secondary to artemisinin: A case report. 9,	O
7 ²	Epigallocatechin-3-gallate Mo nanoparticles (EGM NPs) efficiently treat liver injury by strongly reducing oxidative stress, inflammation and endoplasmic reticulum stress. 13,	O
71	Kratom-Associated Mixed Cholestatic-Hepatocellular Liver Injury in a Patient With Long COVID: A case Report. 2022 , 15, 117954762211328	0
70	Drug-Induced Liver Injury after IVF: comorbidity, forced polypharmacy. 2022 , 224-238	O
69	Antioxidant-Based Preventive Effect of Phytochemicals on Anticancer Drug-Induced Hepatotoxicity.	0
68	Histological and serological features of acute liver injury after SARS-CoV-2 vaccination. 2022 , 100605	O
67	The effects of rhein on D-GalN/LPS-induced acute liver injury in mice: Results from gut microbiome-metabolomics and host transcriptome analysis. 13,	0
66	A review of herb-induced liver injury in mainland china. 13,	Ο
65	Clinical assessment of suspected drug-induced liver injury and its management.	O
64	The use of Andrographis paniculata and its effects on liver biochemistry of patients with gastrointestinal problems in Thailand during the COVID-19 pandemic: a cross sectional study. 2022 , 12,	O
63	The Postoperative Patient. 2023 , 75-83	0
62	A case of autoimmune hepatitis following administration of the COVID19 vaccine. 2022 , 63, 491-499	Ο
61	Metabolomics- and systems toxicology-based hepatotoxicity mechanism of Sophorae Tonkinensis Radix et Rhizoma in rats. 13,	0
60	ONOOtriggered fluorescence H2S donor for mitigating drug-induced liver injury. 2023 , 378, 133131	O
59	Hepatic Injury from Chemotherapy. 2022 , 409-416	O
58	Immunotherapy for Cancer: Common Gastrointestinal, Liver, and Pancreatic Side Effects and Their Management. 2022 , 117, 1917-1932	Ο
57	Acute severe hepatitis outbreak in children: A perfect storm. What do we know, and what questions remain?. 13,	0
56	Nitrofurantoin-induced liver injury: long-term follow-up in two prospective DILI registries.	O

55	Cholestatic liver injury: A rare but fatal complication during and after COVID-19 infection. 11, 435-442	О
54	The immunological mechanisms and therapeutic potential in drug-induced liver injury: lessons learned from acetaminophen hepatotoxicity. 2022 , 12,	1
53	LIVER INJURY INDUCED BY HERBAL AND DIETARY SUPPLEMENTS: A POOLED ANALYSIS OF CASE REPORTS. 2022 , 59, 522-530	0
52	Evaluation of factors affecting epidermal growth factor receptor tyrosine kinase inhibitor-induced hepatotoxicity in Japanese patients with non-small cell lung cancer: a two-center retrospective study. 2022 , 8,	O
51	Drug-Induced Liver Injury in Hospitalized Patients during SARS-CoV-2 Infection. 2022, 58, 1848	1
50	Use of mesenchymal stem cells to accelerate regeneration processes in acute toxic liver injury in an experiment. 2022 , 62, 761-766	O
49	Role of Hepatocyte Transporters in Drug-Induced Liver Injury (DILI)Ih Vitro Testing. 2023, 15, 29	0
48	Remdesivir-Induced Liver Injury in a Patient With Coronavirus Disease 2019 and History of Congestive Hepatopathy. 2022 ,	0
47	Wolfberry enhanced the abundance of Akkermansia muciniphila by YAP1 in mice with acetaminophen-induced liver injury. 2023 , 37,	0
46	Potential benefit and lack of serious risk from corticosteroids in drug-induced liver injury: An international, multicentre, propensity score-matched analysis.	O
45	Infliximab (IFX)-Biosimilar Induced Drug-Induced Liver Injury (DILI): A Case Report. 2022,	0
44	Ceftriaxone-induced cholestatic hepatitis in a child: A case report and a review of the literature. 10,	Ο
43	Endoplasmic reticulum stress regulates autophagic response that is involved in Saikosaponin a-induced liver cell damage. 2022 , 105534	0
42	Discontinuation of immunosuppression in patients with immune-mediated drug-induced liver injury or idiopathic autoimmune hepatitis: A casefontrol study.	O
41	Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives. 13,	0
40	COVID-19 and liver injury: An ongoing challenge. 29, 257-271	O
39	Hepatotoxicity of Drugs Used in Multiple Sclerosis, Diagnostic Challenge, and the Role of HLA Genotype Susceptibility. 2023 , 24, 852	0
38	Severe Drug-Induced Liver Injury From Over-the-Counter Medication. 2023,	O

37	Experience of Using Remdesivir in Patients with Novel Coronavirus Infection. 2022, 10, 365-380	Ο
36	Intensivtherapie bei akutem und chronischem Leberversagen. 2022 , 1-25	O
35	Hepatic and pulmonary involvement in a patient with PR3-ANCA vasculitis following SARS-CoV-2 vaccination: a case report.	О
34	Drug-induced liver injury: An overview and update. 2023,	O
33	Abordaje comíli del paciente con psoriasis y riesgo de esteatosis heplica metablica: recomendaciones de un grupo de expertos multidisciplinar. 2023 ,	О
32	Plasma Sphingoid Base Profiles of Patients Diagnosed with Intrinsic or Idiosyncratic Drug-induced Liver Injury. 2023 , 24, 3013	O
31	Better understanding of ICI-induced cholangitis for better management. 2023 , 11, e006730	0
30	Retracted and Republished from: G ut Microbiota Mediates the Therapeutic Effect of Monoclonal Anti-TLR4 Antibody on Acetaminophen-Induced Acute Liver Injury in Mice[] 2023 , 11,	O
29	Abdominal pain accompanied by elevated serum inflammatory markers and biliary enzymes for diagnosing immune checkpoint inhibitor-induced sclerosing cholangitis.	О
28	A human liver organoid screening platform for DILI risk prediction. 2023 , 78, 998-1006	O
27	Hepatobiliary disease after bone marrow transplant. 2023 , 17, 129-143	О
26	Acetaminophen-induced hepatotoxicity predominantly via inhibiting Nrf2 antioxidative pathway and activating TLR4-NF-B-MAPK inflammatory response in mice. 2023 , 252, 114590	O
25	Molecular Mechanisms of Hepatotoxicity. 2023 , 24, 3791	О
24	Autoimmunity associates with severity of illness in elderly patients with drug-induced liver injury.	O
23	Selective Androgen Receptor Modulators (SARMs)-Induced Liver Injury: A Case Report and Review of Literature. 2023 ,	O
22	Gut microbiota affects sensitivity to immune-mediated isoniazid-induced liver injury. 2023 , 160, 114400	O
21	The Evolving Profile of Idiosyncratic Drug-Induced Liver Injury. 2023,	О
20	Alanine aminotransferase assay biosensor platform using silicon nanowire field effect transistors. 2023 , 2,	0

19	Intrahepatic infiltration of activated CD8+ T cells and mononuclear phagocyte is associated with idiosyncratic drug-induced liver injury. 14,	0
18	Noncirrhotic portal hypertension misdiagnosed as liver cirrhosis: A rare case. 2023 , 2, 40-42	O
17	Toxic reactions of non-steroidal anti-inflammatory drugs in the Russian Federation, analysis of the national database Pharmacovigilance (12023, 73-82)	0
16	Evaluation of Adverse Drug Reaction Caused by Concomitant Use of Trimethoprim-Sulfamethoxazole and Methotrexate in Pediatric Acute Lymphoblastic Leukemia Patients. 2023 , 40, 87-96	0
15	An Immunological Perspective on the Mechanism of Drug Induced Liver Injury: Focused on Drugs for Treatment of Hepatocellular Carcinoma and Liver Transplantation. 2023 , 24, 5002	0
14	The exposome and liver disease - how environmental factors affect liver health. 2023,	o
13	Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort. 2023, 5, 100719	0
12	Leberfunktionsstflungen bei geriatrischen Patienten. 2023 , 18, 143-154	o
11	Incidence, clinical features and risk factors of tacrolimus induced idiosyncratic liver injury in renal transplant recipients: A nested case-control study. 14,	0
10	Therapeutics for treating mpox in humans. 2023 , 2023,	1
9	Peripheral lymphocyte fluctuation as an indicator of severe immune-related adverse events in patients treated with immune checkpoint inhibitors.	
	patients deaded with infinitive checkpoint infinitions.	О
8	Molecular and Clinical Links between Drug-Induced Cholestasis and Familial Intrahepatic Cholestasis. 2023 , 24, 5823	0
7	Molecular and Clinical Links between Drug-Induced Cholestasis and Familial Intrahepatic	
	Molecular and Clinical Links between Drug-Induced Cholestasis and Familial Intrahepatic Cholestasis. 2023 , 24, 5823 Prediction of Fatty Liver Disease in a Chinese Population Using Machine-Learning Algorithms. 2023 ,	o
7	Molecular and Clinical Links between Drug-Induced Cholestasis and Familial Intrahepatic Cholestasis. 2023, 24, 5823 Prediction of Fatty Liver Disease in a Chinese Population Using Machine-Learning Algorithms. 2023, 13, 1168	0
7	Molecular and Clinical Links between Drug-Induced Cholestasis and Familial Intrahepatic Cholestasis. 2023, 24, 5823 Prediction of Fatty Liver Disease in a Chinese Population Using Machine-Learning Algorithms. 2023, 13, 1168 Drug-induced liver injury: a comprehensive review. 2023, 16, 175628482311634 Acetaminophen-induced liver injury: Molecular mechanism and treatments from natural products.	0 0
7	Molecular and Clinical Links between Drug-Induced Cholestasis and Familial Intrahepatic Cholestasis. 2023, 24, 5823 Prediction of Fatty Liver Disease in a Chinese Population Using Machine-Learning Algorithms. 2023, 13, 1168 Drug-induced liver injury: a comprehensive review. 2023, 16, 175628482311634 Acetaminophen-induced liver injury: Molecular mechanism and treatments from natural products. 14, Hepatic Venous Occlusion Type of Buddthiari Syndrome versus Pyrrolizidine Alkaloid-Induced	0 0 0

Association between the Treatment Pattern of Drug-Induced Liver Injury and Clinical Outcomes: A Retrospective Study. **2023**, 2023, 1-7

О